Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains about whether immunotherapies increase the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Korsukewitz, Catharina, Reddel, Stephen W., Bar-Or, Amit, Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341707/
https://www.ncbi.nlm.nih.gov/pubmed/32641860
http://dx.doi.org/10.1038/s41582-020-0385-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341707/
https://www.ncbi.nlm.nih.gov/pubmed/32641860
http://dx.doi.org/10.1038/s41582-020-0385-8

Ejemplares similares